Prostate cancer (PC) is a major global health issue, and its management remains controversial. A refined understanding of how aberrant signaling drives prostate carcinogenesis will help develop better prognostic biomarkers and therapeutic targets. FGF receptor and ERK5 are signaling molecules implicated in clinical PC. Work in our laboratory continues to explore the significance of these signaling pathways of interest, and to apply in vitro and in vivo models to investigate tumour biology and to develop specific small molecule inhibitors. Working closely with colleagues in National Health Service, Glasgow University and the Institute, we are developing infrastructure required for the necessary biorespository and other ongoing translational research programmes.